169 related articles for article (PubMed ID: 16557239)
21. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
McLornan D; Percy M; McMullin MF
Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
[No Abstract] [Full Text] [Related]
22. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
Berger R
Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
[No Abstract] [Full Text] [Related]
23. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
[TBL] [Abstract][Full Text] [Related]
24. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
[TBL] [Abstract][Full Text] [Related]
25. Novel mutations in the FLT3 gene in adult patients with refractory acute myeloid leukemia.
Choi Y; Kim HJ; Park BH; Min WS; Kim CC
Leukemia; 2005 Jan; 19(1):141-3. PubMed ID: 15510198
[No Abstract] [Full Text] [Related]
26. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
[No Abstract] [Full Text] [Related]
27. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
28. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.
Chen W; Jones D; Medeiros LJ; Luthra R; Lin P
Br J Haematol; 2005 Sep; 130(5):726-8. PubMed ID: 16115128
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
31. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M
Br J Haematol; 2006 Aug; 134(3):341-3. PubMed ID: 16787500
[No Abstract] [Full Text] [Related]
32. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
33. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.
Pesu M; O'Shea J; Hennighausen L; Silvennoinen O
Mol Interv; 2005 Aug; 5(4):211-5. PubMed ID: 16123535
[No Abstract] [Full Text] [Related]
34. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.
James C; Delhommeau F; Marzac C; Teyssandier I; Couédic JP; Giraudier S; Roy L; Saulnier P; Lacroix L; Maury S; Tulliez M; Vainchenker W; Ugo V; Casadevall N
Leukemia; 2006 Feb; 20(2):350-3. PubMed ID: 16341032
[No Abstract] [Full Text] [Related]
35. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
36. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
37. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
[TBL] [Abstract][Full Text] [Related]
38. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H; MacLeod RA; Zaborski M; Drexler HG
Leukemia; 2006 Mar; 20(3):471-6. PubMed ID: 16408098
[TBL] [Abstract][Full Text] [Related]
39. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
40. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
